SonoVascular has forged a partnership with Lantheus to use the latter’s microbubbles in combination with its SonoThrombectomy System for the treatment of venous thromboembolism (VTE).
The SonoThrombectomy System is a pharmaco-mechanical ultrasound-based thrombectomy system. It uses microbubble-mediated cavitation to treat VTE.
The clinical supply agreement between SonoVascular and Lantheus is intended for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
SonoThrombectomy integrates ultrasound, microbubbles, a low-dose thrombolytic drug, and mechanical retrieval or aspiration, delivered through an intravascular catheter system.
SonoVascular, which is based in North Carolina, has designed the system to tackle and surpass the shortcomings and constraints of existing interventional devices.
The SonoThrombectomy System is a catheterisation laboratory-based solution aimed at reducing clot burden, reducing thrombolytic dosage and duration, optimising safety and effectiveness, and eliminating intensive care unit (ICU) treatment needs for patients.
Lantheus chief business officer Etienne Montagut said: “We are excited to partner with SonoVascular to extend our microbubble franchise into a novel treatment for VTE.
“Our collaboration with SonoVascular leverages both companies’ strengths to help change the paradigm in the treatment of venous disease – a large and growing clinical condition.”
The SonoThrombectomy System will enter into first-in-human (FIH) trials this year, in collaboration with Lantheus, following successful in vitro and in vivo preclinical studies.
The FIH studies will assess the system’s safety and feasibility in treating deep vein thrombosis (DVT) and pulmonary embolism (PE) before advancing to US studies for both conditions.
Lantheus will provide its microbubbles and activation devices, while SonoVascular will oversee clinical trials, regulatory submissions, and commercialisation.
Additionally, upon conclusion of a FIH study, SonoVascular holds the option to engage in a long-term commercial supply agreement with Lantheus.
SonoVascular founder and CEO Daniel Estay said: “SonoVascular is honoured to have the opportunity to partner with Lantheus, a leader in microbubble development.
“Our SonoThrombectomy System, combined with Lantheus’ microbubbles, is designed to provide a true, next generation solution for the treatment of DVT and PE that overcomes the drawbacks associated with catheter-based thrombectomy and thrombolysis devices.”
